Navigation Links
Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
Date:9/26/2011

lateusa.com/">wilate® is a plasma-derived, stable, highly purified concentrate of freeze-dried human von Willebrand factor (VWF) and coagulation factor VIII (FVIII). Two well-established virus inactivation steps are incorporated into the manufacturing process of wilate®, specifically a solvent/detergent (S/D) and terminal dry heat treatment.

For more information on the research, entitled "Clinical Study to Investigate the Efficacy and Safety of Human Factor VWF/VIII Concentrate (wilate®) in Subject with Inherited Type 3 Von Willebrand Disease (VWD) who Undergo Major Surgical Procedures (WONDERS)," please visit www.clinicaltrials.gov. U.S. researchers interested in participating in the study should contact Sylvia Werner, Octapharma Associate Director Clinical Operations – Coagulation, at (201) 604-1149 or sylvia.werner@octapharma.com.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam®  (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma'
'/>"/>

SOURCE Octapharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
2. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
3. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
4. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
5. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
6. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
10. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
11. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- Silver Creek Pharmaceuticals, Inc. announced today the award ... the National Institute of Health (NIH). ... based biotechnology company that discovers and develops targeted ... This award will be used to advance their proprietary ... heart attack. Silver Creek,s Smart Growth Factors ...
(Date:5/5/2015)... 2015 GW Pharmaceuticals plc (Nasdaq: GWPH, ... company focused on discovering, developing and commercializing novel ... today the closing of the previously announced offering ... 1,600,000 American Depositary Shares (ADSs) at a price ... approximately $179.2 million (before deducting underwriting discount, commissions ...
(Date:5/5/2015)... May 5, 2015  IBM Watson Health (NYSE: IBM ... and Mayo Clinic to advance patient health ... Health Records (EHRs). As Watson,s capabilities are ... and thorough analysis of the medical factors that could impact ... more than 350 customers – some of the largest and ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 2IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 3IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 4
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
... for an Antiplatelet Therapy that, Combined, with Aspirin, ... and Aspirin, According to ... Mass., May 15 Decision Resources, one of ... and,healthcare issues, finds that Daiichi Sankyo/Eli Lilly,s Effient ...
Cached Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3
(Date:5/5/2015)... 05, 2015 Hundreds of ... on behalf of men who allegedly suffered ... of prescription testosterone replacement therapies continue to ... underway in U.S. District Court, Northern District ... May 1st, defendants AbbVie, Inc., Auxilium Pharmaceuticals, ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
(Date:5/5/2015)... Skedans Systems a division of ... Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems ... developers, provides tooling to deliver real time information for ... Skedans Sensor Collaboration Platform is a single unified cloud ... Things, Web Real Time Communications (WebRTC), and commercial Unmanned ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 MAP Health ... and revenue cycle management for addiction treatment facilities, announced ... Vice President of Business Development. Mr. Mooney, who has ... treatment field, will be responsible for developing new strategic ... of MAP’s core products and new initiatives. , Prior ...
(Date:5/5/2015)... 2015 Okyanos, the leader in ... The study was conducted to determine the emotional impact ... and sports-related injuries have had on those affected. ... most prevalent symptom reported at 73%, followed by 66% ... and bending over. Over half of respondents, 56%, said ...
Breaking Medicine News(10 mins):Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
... surgery reduces potentially serious kidney complications, according to a ... Journal of the American Society Nephrology (JASN). ... are performed around the world. Unfortunately, many patients who ... often due to decreased blood flow to the kidneys ...
... 14 (HealthDay News) -- Trying to make the best of the ... with losing their jobs, a new United Kingdom study finds. ... their job loss were able to see the event as a ... and study. They also took a contemplative view of their ...
... has found that the majority of individuals with substance ... found that opioid users, in particular, showed a decline ... These findings appear online in the Journal of ... and internal medicine faculty from Boston University investigated the ...
... , THURSDAY, April 14 (HealthDay News) -- The best ... new study suggests. Supportive reactions by managers and ... to positive changes in the workplace, while chastising or ... chair of the human resource management department at Temple ...
... --- Battling an illness, lack of sleep and strange ... sorts. For seniors, hospitalizations actually may cause ... according to a new Northwestern Medicine study. ... the hospital stay, the study found. But immediately following ...
... circadian system that controls normal sleep patterns is regulated ... according to a study published online on April 14th ... Neuroscientists from Tufts University School of Medicine found that ... to altered daily rhythms, an indication that these star-shaped ...
Cached Medicine News:Health News:Statins may protect against kidney complications following elective surgery 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Compassion, Not Punishment, Helps Diffuse Workplace Anger: Study 2Health News:Temporary memory loss strikes hospitalized seniors 2Health News:Rising star of brain found to regulate circadian rhythms 2
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
Medicine Products: